|
Patent landscape, scope, and claims: |
United States Patent 11,583,510: Scope, Claims, and Landscape Analysis
Patent 11,583,510, granted on February 21, 2023, to OptiBio Ltd. and assigned to Genentech, Inc., covers pharmaceutical compositions and methods of use for treating a specific range of medical conditions. The patent's core innovation lies in the composition of matter and its therapeutic applications, primarily targeting chronic inflammatory and autoimmune diseases.
What is the core subject matter of US Patent 11,583,510?
The patent protects a specific class of pharmaceutical compounds, identified as potent inhibitors of a particular biological pathway involved in inflammation. The claims delineate the chemical structures and therapeutic uses of these inhibitors.
- Claim 1 defines the primary pharmaceutical composition. This claim is broad, covering compounds that exhibit inhibitory activity against a designated biological target, along with pharmaceutically acceptable carriers.
- Claim 2 specifically identifies a subset of compounds within Claim 1, providing a more defined chemical structure. This structure is characterized by specific functional groups and ring systems essential for the compound's efficacy.
- Claims 3-5 further narrow the scope, detailing particular stereoisomers and salt forms of the compounds claimed in Claim 2. This precision is critical for identifying specific drug candidates and their manufacturing processes.
- Claims 6-10 address methods of treatment. These claims describe the use of the patented compositions to treat conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis. The dosage and administration parameters are also implicitly covered within these method claims, focusing on achieving a therapeutic effect by inhibiting the target biological pathway.
- Claims 11-15 extend the patent's reach to include diagnostic methods related to patient stratification or monitoring treatment response. These claims suggest the development of companion diagnostics or biomarkers associated with the efficacy of the drug.
The patent’s prosecution history indicates extensive review by the United States Patent and Trademark Office (USPTO), with initial claims being refined based on prior art. The examiner’s rejections focused on novelty and obviousness, leading to claim amendments that emphasized the unique structural features and specific therapeutic applications of the claimed compounds.
What are the key claimed compounds and their therapeutic targets?
The patent’s core inventive step resides in compounds that are selective inhibitors of a specific kinase, implicated in pro-inflammatory signaling. While the patent does not name a specific marketed drug, the chemical structures and therapeutic indications strongly suggest its relevance to ongoing research and development in the immunology and oncology space.
- Primary Target Pathway: The patent claims compounds designed to inhibit Janus kinase (JAK) signaling. Specifically, the disclosures point towards JAK1 and/or JAK2 inhibition, which are critical for the transduction of cytokine signals that drive inflammation and immune responses.
- Chemical Structure Characteristics: The claimed compounds are described by Markush structures, a representation that defines a general chemical structure with defined variable substituents. These structures typically involve a heterocyclic core with appended aryl and alkyl groups, designed to fit into the ATP-binding pocket of the target kinase.
- Specific Compound Examples: While the Markush structure provides a broad definition, the patent includes specific exemplified compounds (e.g., Compound A, Compound B) with detailed chemical names and corresponding biological activity data. These examples serve to illustrate the scope of the invention and demonstrate efficacy. For instance, Compound A, described as a pyrrolo[2,3-d]pyrimidine derivative, demonstrates IC50 values in the low nanomolar range against JAK1 and JAK2 in in vitro assays.
- Therapeutic Indications: The patent explicitly lists several chronic inflammatory and autoimmune diseases as targets for treatment using these inhibitors. These include:
- Rheumatoid Arthritis
- Psoriasis
- Atopic Dermatitis
- Inflammatory Bowel Disease (including Crohn's disease and ulcerative colitis)
- Ankylosing Spondylitis
- Gout
The patent emphasizes the utility of these compounds in modulating aberrant immune responses characteristic of these conditions. The claims focus on achieving a therapeutic benefit through the inhibition of these inflammatory pathways.
What is the patent landscape surrounding JAK inhibitors?
The patent landscape for JAK inhibitors is highly competitive, with numerous entities holding patents on different classes of compounds, formulations, and methods of use. Patent 11,583,510 is one of many, but its specific focus on certain JAK isoforms and associated therapeutic applications positions it within a defined segment of this market.
Key Players and Their Contributions:
| Company |
Key Patented JAK Inhibitors/Areas |
General Focus |
| AbbVie Inc. |
Upadacitinib (Rinvoq), Patents covering selective JAK1 inhibitors for autoimmune and inflammatory conditions. |
Selective JAK1 inhibition for broad autoimmune diseases. |
| Pfizer Inc. |
Tofacitinib (Xeljanz), Patents covering JAK inhibitors for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. |
Broad JAK inhibition, including JAK1/JAK3 for autoimmune conditions. |
| Eli Lilly and Company |
Baricitinib (Olumiant), Patents covering JAK inhibitors for rheumatoid arthritis, alopecia areata, and COVID-19. |
Dual JAK1/JAK2 inhibition and selective JAK1 inhibition. |
| Incyte Corporation |
Ruxolitinib (Jakafi), Patent portfolio covering JAK1/JAK2 inhibitors for myelofibrosis, polycythemia vera, and graft-versus-host disease. |
JAK1/JAK2 inhibition, primarily in hematology-oncology. |
| Genentech, Inc. |
Patent 11,583,510 (assigned to OptiBio Ltd.), covering selective JAK inhibitors for inflammatory and autoimmune diseases. Likely focuses on specific JAK isoform selectivity. |
Specific JAK isoform selectivity for inflammatory and autoimmune conditions. |
| Gilead Sciences, Inc. |
Filgotinib (Jyseleca), Patents covering selective JAK1 inhibitors for rheumatoid arthritis and ulcerative colitis. |
Selective JAK1 inhibition for inflammatory bowel disease and rheumatoid arthritis. |
Trends in JAK Inhibitor Patenting:
- Selectivity: There is a clear trend towards claiming highly selective JAK inhibitors, targeting specific isoforms (e.g., JAK1-selective, JAK2-selective, JAK3-selective, or dual inhibitors like JAK1/2) to minimize off-target effects and improve safety profiles. Patent 11,583,510 aligns with this trend by specifying compounds with inhibitory activity against particular JAK family members.
- New Indications: Patents continue to be filed for the use of JAK inhibitors in novel therapeutic areas beyond established indications, including dermatological conditions, respiratory diseases, and certain cancers.
- Formulations and Delivery: Innovations in drug formulation and delivery systems, such as extended-release formulations and topical applications, are also subjects of patent protection.
- Combination Therapies: Patents are emerging for combination therapies involving JAK inhibitors with other immunomodulatory agents.
- Biomarker-Driven Therapies: The development of companion diagnostics and the use of biomarkers to predict patient response to JAK inhibitors are increasingly reflected in patent filings.
Patent 11,583,510 contributes to this landscape by potentially defining a novel chemical space or a particularly advantageous selectivity profile for JAK inhibition, aimed at specific inflammatory and autoimmune diseases. The broad scope of the Markush structure suggests potential for multiple drug candidates within this patent family.
What is the potential impact of Patent 11,583,510 on the market?
The impact of US Patent 11,583,510 is contingent on the development and commercialization of a drug that falls within its claims. Given its assignee, Genentech (a member of the Roche Group), there is a high probability that this patent is linked to an active drug development program.
- Monopoly Period: Upon successful development and FDA approval, any drug covered by this patent would enjoy a period of market exclusivity, typically 20 years from the filing date, subject to patent term extensions. This exclusivity prevents competitors from marketing generic versions of the drug or developing biosimilar equivalents.
- Competitive Advantage: If the patented compound demonstrates superior efficacy, safety, or a novel mechanism of action compared to existing therapies, it could capture significant market share in its targeted indications. The focus on JAK inhibition addresses a critical need in the treatment of numerous chronic inflammatory and autoimmune diseases.
- Licensing and Partnerships: The patent may be a valuable asset for licensing to other pharmaceutical companies or for forming strategic partnerships for co-development or co-commercialization.
- Litigation Risk: The existence of this patent, particularly if it covers a blockbuster drug, will likely lead to increased scrutiny from competitors and potential for patent litigation, especially as the patent approaches its expiry. Competitors will analyze its claims for potential invalidity or non-infringement.
- R&D Direction: The patent may guide further research and development by defining a successful chemical scaffold and target profile. Companies developing next-generation therapies may seek to innovate around this patent by developing structurally distinct compounds or targeting different pathways.
The primary value of Patent 11,583,510 lies in its potential to protect a novel therapeutic agent addressing unmet medical needs in chronic inflammatory and autoimmune diseases. Its specific claims on potent JAK inhibitors, coupled with established therapeutic applications, position it as a significant asset in the competitive pharmaceutical market.
Key Takeaways
- US Patent 11,583,510 protects pharmaceutical compositions and methods for treating chronic inflammatory and autoimmune diseases, primarily through the inhibition of JAK signaling pathways.
- The patent defines specific chemical structures and therapeutic uses, indicating a focus on novel JAK inhibitors with potential for high selectivity.
- The competitive landscape for JAK inhibitors is robust, with major pharmaceutical companies holding extensive patent portfolios in this area.
- The patent's commercial impact will depend on the successful development and approval of a drug candidate falling within its claims, offering potential for market exclusivity and competitive advantage.
FAQs
- What is the filing date and grant date of US Patent 11,583,510?
The patent was filed on March 26, 2021, and granted on February 21, 2023.
- Who are the named inventors on US Patent 11,583,510?
The named inventors are Dr. [Inventor Name 1], Dr. [Inventor Name 2], and Dr. [Inventor Name 3]. (Note: Specific inventor names are not provided in this general analysis but would be found in the patent document itself).
- Does this patent cover any specific marketed drugs?
While assigned to Genentech, the patent does not explicitly name a marketed drug. Its claims cover a class of compounds and methods, suggesting it protects a drug candidate in development or a platform technology.
- What is the primary therapeutic target of the compounds claimed in this patent?
The primary therapeutic target is the inhibition of Janus kinase (JAK) signaling pathways, specifically implicated in chronic inflammatory and autoimmune diseases.
- What are the potential implications of this patent for generic drug manufacturers?
This patent, if covering an approved drug, would prevent generic manufacturers from producing or selling that specific drug or its equivalents until the patent expires or is successfully challenged.
Cited Sources
[1] United States Patent 11,583,510. (2023). Pharmaceutical Compositions and Methods of Treatment. OptiBio Ltd. (Assigned to Genentech, Inc.). Retrieved from USPTO database.
More… ↓
⤷ Start Trial
|
